[The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
Zhonghua Wai Ke Za Zhi
; 58(7): 481-485, 2020 Jul 01.
Article
in Zh
| MEDLINE
| ID: mdl-32610414
ABSTRACT
Pancreatic cancer has a high degree of malignancy and a poor prognosis, and the treatment effect is still not ideal. For patients with advanced pancreatic cancer, extended surgery for pancreatic cancer alone cannot benefit the patients. However, with the development of neoadjuvant therapy in the field of pancreatic cancer, some cases have obtained radical operation. Studies have shown that neoadjuvant therapy, combined with extended surgery for pancreatic cancer, can improve the overall prognosis of patients, indicating that surgical techniques themselves are still useful. In this article, combined with the relevant guidelines and clinical research progress of pancreatic cancer, the controversy and progress of the extended surgery for pancreatic cancer in the context of neoadjuvant therapy is summarized, and the resectability and prognosis evaluation index after neoadjuvant therapy is discussed, in order to standardize the treatment of pancreatic cancer, enhance the understanding of extended surgery for pancreatic cancer, and further improve the prognosis of pancreatic cancer.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatectomy
/
Pancreatic Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Neoadjuvant Therapy
Type of study:
Guideline
/
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Wai Ke Za Zhi
Year:
2020
Document type:
Article
Affiliation country:
China